Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + bendamustine + rituximab
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Polatuzumab vedotin + bendamustine + rituximab (Pola-BR) is a combination chemoimmunotherapy regimen being evaluated for the treatment of relapsed or refractory mantle cell lymphoma (MCL), particularly in patients who have failed prior Bruton's tyrosine kinase (BTK) inhibitor therapy. The regimen consists of polatuzumab vedotin, a CD79b-directed antibody-drug conjugate; bendamustine, a bifunctional alkylating agent; and rituximab, a CD20-directed monoclonal antibody. This specific study is led by the Czech Lymphoma Study Group (CLSG) as a Phase II trial to address the high unmet need in post-BTKi MCL patients. Polatuzumab vedotin delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) directly to CD79b-expressing B-cells, while rituximab induces immune-mediated cell death and bendamustine causes DNA cross-linking.
- Other names
- polatuzumab vedotin plus bendamustine and rituximab
02
Targets
Beyond the preview
Go deeper on polatuzumab vedotin + bendamustine + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + bendamustine + rituximab.